↓ Skip to main content

Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, January 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
114 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods
Published in
Journal of Pharmaceutical Policy and Practice, January 2015
DOI 10.1186/s40545-015-0029-3
Pubmed ID
Authors

Mona Jaberidoost, Laya Olfat, Alireza Hosseini, Abbas Kebriaeezadeh, Mohammad Abdollahi, Mahdi Alaeddini, Rassoul Dinarvand

Abstract

Pharmaceutical supply chain is a significant component of the health system in supplying medicines, particularly in countries where main drugs are provided by local pharmaceutical companies. No previous studies exist assessing risks and disruptions in pharmaceutical companies while assessing the pharmaceutical supply chain. Any risks affecting the pharmaceutical companies could disrupt supply medicines and health system efficiency. The goal of this study was the risk assessment in pharmaceutical industry in Iran considering process's priority, hazard and probability of risks. The study was carried out in 4 phases; risk identification through literature review, risk identification in Iranian pharmaceutical companies through interview with experts, risk analysis through a questionnaire and consultation with experts using group analytic hierarchy process (AHP) method and rating scale (RS) and risk evaluation of simple additive weighting (SAW) method. In total, 86 main risks were identified in the pharmaceutical supply chain with perspective of pharmaceutical companies classified in 11 classes. The majority of risks described in this study were related to the financial and economic category. Also financial management was found to be the most important factor for consideration. Although pharmaceutical industry and supply chain were affected by current political conditions in Iran during the study time, but half of total risks in the pharmaceutical supply chain were found to be internal risks which could be fixed by companies, internally. Likewise, political status and related risks forced companies to focus more on financial and supply management resulting in less attention to quality management.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 2 2%
Malaysia 1 <1%
Iran, Islamic Republic of 1 <1%
Unknown 110 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 31 27%
Student > Bachelor 17 15%
Student > Ph. D. Student 14 12%
Lecturer 9 8%
Student > Doctoral Student 7 6%
Other 26 23%
Unknown 10 9%
Readers by discipline Count As %
Engineering 30 26%
Business, Management and Accounting 29 25%
Pharmacology, Toxicology and Pharmaceutical Science 8 7%
Social Sciences 6 5%
Medicine and Dentistry 5 4%
Other 15 13%
Unknown 21 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2015.
All research outputs
#7,066,781
of 12,521,542 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#107
of 159 outputs
Outputs of similar age
#97,779
of 226,204 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#1
of 1 outputs
Altmetric has tracked 12,521,542 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 159 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,204 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them